Alpha Tau Medical Ltd.(DRTS)Stock Analysis

DRTS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alpha Tau Medical Ltd. (DRTS), a Healthcare sector company. DRTS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), Alpha Tau Medical Ltd. reports net income of $-42.6M, free cash flow of $-32.8M. Top institutional holders of DRTS by reported 13-F value include Fisher Funds Management LTD, HighTower Advisors,, Aquamarine Financial (Cayman) Ltd, based on the most recent SEC filings. DRTS trades on the Nasdaq exchange and files with the SEC under CIK 1871321. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alpha Tau Medical Ltd. directly from SEC EDGAR.